- Home
- OMER vs NLOP Comparison
OMER vs NLOP Comparison
Compare OMER & NLOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- NLOP
- Stock Information
- Founded
- OMER 1994
- NLOP 2022
- Country
- OMER United States
- NLOP United States
- Employees
- OMER N/A
- NLOP N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- NLOP
- Sector
- OMER Health Care
- NLOP
- Exchange
- OMER Nasdaq
- NLOP Nasdaq
- Market Cap
- OMER 532.0M
- NLOP 470.6M
- IPO Year
- OMER 2009
- NLOP N/A
- Fundamental
- Price
- OMER $9.18
- NLOP $31.85
- Analyst Decision
- OMER Buy
- NLOP Strong Buy
- Analyst Count
- OMER 4
- NLOP 1
- Target Price
- OMER $22.50
- NLOP $46.00
- AVG Volume (30 Days)
- OMER 422.2K
- NLOP 145.9K
- Earning Date
- OMER 03-31-2025
- NLOP 01-01-0001
- Dividend Yield
- OMER N/A
- NLOP 1.07%
- EPS Growth
- OMER N/A
- NLOP N/A
- EPS
- OMER N/A
- NLOP N/A
- Revenue
- OMER N/A
- NLOP $160,911,000.00
- Revenue This Year
- OMER N/A
- NLOP N/A
- Revenue Next Year
- OMER N/A
- NLOP N/A
- P/E Ratio
- OMER N/A
- NLOP N/A
- Revenue Growth
- OMER N/A
- NLOP N/A
- 52 Week Low
- OMER $2.61
- NLOP $22.16
- 52 Week High
- OMER $13.60
- NLOP $34.38
- Technical
- Relative Strength Index (RSI)
- OMER 51.19
- NLOP 49.95
- Support Level
- OMER $9.06
- NLOP $30.69
- Resistance Level
- OMER $9.43
- NLOP $34.38
- Average True Range (ATR)
- OMER 0.52
- NLOP 0.85
- MACD
- OMER 0.08
- NLOP 0.06
- Stochastic Oscillator
- OMER 52.25
- NLOP 31.46
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About NLOP Net Lease Office Properties of Beneficial Interest
Net Lease Office Properties is a real estate investment trust. Through its subsidiaries it owns, operates, and finances office buildings. Its properties are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its portfolio includes approximately 1.5 million square feet of Green-Certified Buildings, 4 LEED-Certified Buildings, and 1 BREEAM-Certified Building.